SEC Tracker
Get the app
EXEL · XBRL financial data

Exelixis financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (EXEL's year ends in early January)

In millions of dollarsDec 29, 2023Mar 29, 2024Jun 28, 2024Sep 27, 2024Jan 3, 2025Apr 4, 2025Jul 4, 2025Oct 3, 2025Jan 2, 2026Apr 3, 2026Jul 3, 2026Oct 2, 2026
Revenue from contracts with customers480*425637540567*555568598599*611629659
Cost of goods and services sold22*21181720*19191926*202126
Research and development245*228211223249*212200199213*200212209
Selling, general and administrative131*114132112134*137135124123*140148155
Operating income (loss)82*29276136163*187214237235*251248268
Other income (expense)(0)*(0)(0)(0)0*(0)0(0)0*000
Income tax expense (benefit)18*12673745*4646598*575165
Net income (loss)86*37226118140*160185194245*210212218
Earnings per share, basic USD per share0.28*0.120.780.410.49*0.570.680.720.92*0.810.850.88
Earnings per share, diluted USD per share0.27*0.120.770.400.48*0.550.650.690.88*0.790.820.85
Weighted average shares, basic millions of shares308*301289286285*279273268266*258251247
Weighted average shares, diluted millions of shares313*306294291294*288284279276*267260256

Balance sheet

CSV

Fiscal quarters (EXEL's year ends in early January)

In millions of dollarsDec 29, 2023Mar 29, 2024Jun 28, 2024Sep 27, 2024Jan 3, 2025Apr 4, 2025Jul 4, 2025Oct 3, 2025Jan 2, 2026Apr 3, 2026Jul 3, 2026Oct 2, 2026
Cash and cash equivalents263260198258217184164376482226281305
Short-term investments732704804—————————
Marketable securities732——931894848627612577551558587
Marketable securities, non-current729——523637619595578604649545508
Inventory172121212225232722272930
Prepaid and other current assets686758706859747776766071
Total current assets1,3181,2921,4771,5501,4681,3971,1811,4021,4431,2091,2511,322
Property and equipment, net12912713012411911511010599969387
Right-of-use asset233———173———159———
Goodwill646464646464646464646464
Total assets2,9422,8042,7732,9602,9482,8372,6782,8242,8442,5942,4942,513
Accounts payable342629593843262530243931
Total current liabilities394373346394404399336374406371362412
Lease liability, non-current190201198194191187180176173170166162
Total liabilities678676653685703706645663683658650680
Accumulated deficit(173)(259)(200)(90)(99)(163)(220)(106)(77)(216)(263)(259)
Total stockholders' equity2,2642,1282,1202,2752,2442,1312,0342,1612,1611,9361,8441,834
Total liabilities and equity2,9422,8042,7732,9602,9482,8372,6782,8242,8442,5942,4942,513
Common shares outstanding (cover page) millions of shares303291285286280273269268260251248244

Cash flows

CSV

Fiscal quarters (EXEL's year ends in early January)

In millions of dollarsDec 29, 2023Mar 29, 2024Jun 28, 2024Sep 27, 2024Jan 3, 2025Apr 4, 2025Jul 4, 2025Oct 3, 2025Jan 2, 2026Apr 3, 2026Jul 3, 2026Oct 2, 2026
Net income (loss)86*37226118140*160185194245*210212218
Stock-based compensation24*1925*23*26*2636*31*20*2933*29*
Depreciation and amortization7*67*7*8*77*7*7*77*7*
Net cash from operating activities11*69120*271*240*21149*290*334*252308*280*
Purchases of property and equipment13*107*8*4*33*1*1*27*2*
Net cash from investing activities62*11282*(217)*(93)*50248*25*27*(51)91*(7)*
Share repurchases209*185264*12*190*284302*104*258*430323*250*
Net cash from financing activities(206)*(184)(262)*6*(188)*(295)(316)*(104)*(255)*(457)(344)*(250)*
Net change in cash(134)*(3)(61)*60*(41)*(34)(19)*212*106*(256)55*23*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Exelixis305659280*244.0M— 10-QOct 2, 2026
Neurocrine Biosciences6421,123395*101.2M— 10-QSep 30, 2026
BIO-TECHNE265321*95*156.8M— 10-KJun 30, 2026
Roivant Sciences1,2481.4(271)722.3M14.2 quarters 10-QJun 30, 2026
United Therapeutics1,803783314*42.9M— 10-QJun 30, 2026
Revolution Medicines815not reported(387)*214.3M10.2 quarters 10-QJun 30, 2026
Biomarin Pharmaceutical7361,025188*193.7M— 10-QSep 30, 2026
Jazz Pharmaceuticals2,0361,243506*64.2M— 10-QSep 30, 2026
Corcept Therapeutics99340143*109.4M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.